iShares Genomics Immunology and Healthcare Index ETF Trust Units

An exchange-traded fund (ETF) is a collection of assets (stocks, bonds, commodities, etc.) that track an underlying index and can be bought on an exchange like individual stocks.

XDNA trades at 32.09 CAD today, its price has risen 1.17% in the past 24 hours. Track more dynamics on XDNA price chart.

XDNA net asset value is 32.07 today — it's risen 6.72% over the past month. NAV represents the total value of the fund's assets less liabilities and serves as a gauge of the fund's performance.

XDNA assets under management is ‪4.75 M‬ CAD. AUM is an important metric as it reflects the fund's size and can serve as a gauge of how successful the fund is in attracting investors, which, in its turn, can influence decision-making.

XDNA price has risen by 6.96% over the last month, and its yearly performance shows a −8.10% decrease. See more dynamics on XDNA price chart.
NAV returns, another gauge of an ETF dynamics, showed a 10.12% increase in three-month performance and has decreased by −6.82% in a year.

XDNA fund flows account for 0.00 CAD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.

Since ETFs work like an individual stock, they can be bought and sold on exchanges (e.g. NASDAQ, NYSE, EURONEXT). As it happens with stocks, you need to select a brokerage to access trading. Explore our list of available brokers to find the one to help execute your strategies. Don't forget to do your research before getting to trading. Explore ETFs metrics in our ETF screener to find a reliable opportunity.

XDNA invests in stocks. See more details in our Analysis section.

No, XDNA isn't leveraged, meaning it doesn't use borrowings or financial derivatives to magnify the performance of the underlying assets or index it follows.

In some ways, ETFs are safe investments, but in a broader sense, they're not safer than any other asset, so it's crucial to analyze a fund before investing. But if your research gives a vague answer, you can always refer to technical analysis.
Today, XDNA technical analysis shows the buy rating and its 1-week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1-month rating XDNA shows the neutral signal. See more of XDNA technicals for a more comprehensive analysis.

Yes, XDNA pays dividends to its holders with the dividend yield of 0.53%.

XDNA trades at a premium (0.10%).
Premium/discount to NAV expresses the difference between the ETF’s price and its NAV value. A positive percentage indicates a premium, meaning the ETF trades at a higher price than the calculated NAV. Conversely, a negative percentage indicates a discount, suggesting the ETF trades at a lower price than NAV.

XDNA shares are issued by BlackRock, Inc.

XDNA follows the NYSE FactSet Global Genomics and Immuno Biopharma Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.

The fund started trading on Apr 26, 2022.